key: cord-0813631-ee5m2zy8
authors: Seage, Catherine Heidi; Semedo, Lenira
title: How Do Patients Receiving Prescribed B(12) Injections for the Treatment of PA Perceive Changes in Treatment During the COVID-19 Pandemic? A UK-Based Survey Study
date: 2021-03-03
journal: J Patient Exp
DOI: 10.1177/2374373521998842
sha: 97e973048015935ed00316a86724af2451baa87c
doc_id: 813631
cord_uid: ee5m2zy8

Pernicious anemia (PA) is a chronic condition that is usually treated using B(12) injections. Due to the pandemic, many patients were prescribed an alternative oral B(12) treatment. There is limited evidence that this is effective at managing symptoms of PA. The aim of this study was to document treatment changes across the United Kingdom and the impact on patient experience. An online survey explored how the treatment of PA has been managed during the early stages of the pandemic; responses were analyzed for a subsample of participants receiving prescribed B(12) injections and where changes in treatment applied (n = 329) using content analysis. The most common reported change was the suspension of injections, with oral B(12) being offered as an alternative treatment. Patients were concerned about the long-term impact that changes would have on their condition management, and many stated that they were dissatisfied with the level of care received. Those who were supported by health care providers to continue their usual treatment reported experiencing improved health and well-being. This study highlights the major impact of treatment changes on patient health outcomes and the need to further support health care professionals with PA management during and beyond the pandemic.

settings. The extent to which PA treatment has been impacted in the United Kingdom is unknown. An online survey was designed to capture individual's experience of PA treatment change during the COVID-19 pandemic. Specific objectives of this study are to (1) establish the extent to which treatment for PA has changed across the United Kingdom, (2) to explore respondents' perceptions on how changes to treatment have been managed within their primary care setting, and (3) to document whether patients have made any changes to how they manage their PA.

The current study received ethical approval from the School of Sport and Health Science Ethics Committee, Cardiff Metropolitan University (reference STa-2872). This study employed a cross-sectional survey design. An online survey was developed to collect patients' experiences during the pandemic. Survey development was informed by current literature and a recent change in guidelines regarding the treatment of PA (4) . This study aligns with the recent UK Patient and Public Involvement (PPI) Standards for research in terms of inclusive opportunities, working together and impact (6) . Patient and Public Involvement input was gained through the PA society, 2 members were consulted from the early stages of research to ensure involvement from those who may benefit from the research (inclusive opportunities), to confirm the survey questions were clear and understandable (working together) as well as to support the dissemination of study results (impact). Eligible participants were those aged over 18 with a confirmed PA diagnosis and who were currently receiving prescribed treatment for their PA as a resident in the United Kingdom. Participants were recruited via online social media platforms including Facebook and Twitter, and the survey link was also sent out to members of the Pernicious Anaemia Society. The survey contained 15 items which were a mixture of closed questions and open-text responses (Supplementary 1). The first section of the survey collated demographic information about the respondents as well as clinical information about their PA. Participants were asked about how their PA is typically treated, and if this has changed during the COVID-19 pandemic.

Survey data were analyzed using descriptive statistics, opentext responses were analyzed using content analysis (7) (8) (9) and managed through NVivo (Version 12) (10) through 1) familiarizing with the data, 2) identifying and condensing meaningful units within responses, 3) generating codes, and 4) developing categories within themes. Both authors, independently coded all the data to inductively generate themes accurately reflecting the data. Themes were revised and discussed, and where there were discrepancies (eg, code names) these were resolved by consensus to reach final themes (11) . Any differences and commonalities in treatment changes across the United Kingdom were documented. Quotes were selected to portray identified themes.

The online survey was live on google forms between June 26, 2020, and October 5, 2020, and was completed by patients across the United Kingdom. In total, there were 683 responses to the survey; of these, 329 participants indicated that they had experienced a change to their prescribed treatment, which was a consequence of the pandemic. All reported percentages are based on this subsample of participants. Table 1 provides an overview of the key demographic and clinical characteristics of this sample.

Participants' ages ranged from 23 years to 87 years, and mean reported age was 53.41 + 13.24. There were 275 females and 52 males; one participant identified as nonbinary and one did not disclose gender. Nearly half of the participants were members of a support group to help them manage their condition. All United Kingdom countries were represented in the data, but most responses were from England (58.05%). Prior to the pandemic, all patients were receiving prescribed treatment in the form of prescribed hydroxocobalamin injections which were typically administered within a health care setting every 8 to 12 weeks. Twenty-one respondents indicated that they self-administered B 12 injections which they purchased alongside prescribed treatment; this was because they perceived the frequency of prescribed injections to be insufficient to manage their symptoms. 

Precautionary measures to deal with the pandemic meant that treatment had changed for many respondents. Changes were experienced mainly by those whose usual care was to have prescribed B 12 administered within a health care setting. The types of treatment changes made were consistent across the United Kingdom with no apparent differences between countries. Decisions to change treatment were mostly initiated by a health care professional with no further discussion with the patient (n ¼ 276). However, for some patients, these changes took effect after a mutual discussion between the patient and their health care provider (n ¼ 42). A small number of individuals requested that they be provided an alternative treatment (n ¼ 4). Often changes were temporary with patients being informed that their health care provider would revert to standard care once it was safe to do so (n ¼ 152). A small proportion of patients had been told that treatment changes were permanent (n ¼ 32). Nearly half of respondents stated that they were unsure how long the change to their treatment would last (n ¼ 143). In most cases, treatment changes meant patients' injections had been suspended and replaced with B 12 tablets and nutritional advice provided. The data analysis identified 8 themes related to treatment changes, which are summarized in Table 2 .

Patients who continued to receive their injections from their health care provider were often required to wait longer to receive their scheduled injections. Some patients were asked to attend a different surgery with social distancing measures in place, while others were asked to wait until their symptoms got worse before contacting their surgery to arrange their appointment. 

It was common for patients whose injections had been suspended to request to self-treat at home. These injections would be administered by themselves, a family member, or a friend who is a health care professional. GPs supported this process by ensuring individuals were trained to safely administer B 12 injections at home. Patients who had been enabled to self-treat (n ¼ 37) embraced the change to their treatment and preferred this to standard treatment. The increased perceptions of control over treatment are illustrated in the quote:

Self-injecting was as quite liberating as I am now not tied to visiting the surgery so frequently. (P2, England) However, some requests to self-treat were not supported; in desperation to receive replacement B 12 , these patients began to source their own injections privately or administer hydroxocobalamin injections bought overseas without a prescription (n ¼ 12). Individuals who decided to self-treat were often able to administer injections at a treatment schedule that was more based on individual need. This group reported a noticeable improvement in their symptoms and quality of life. I now have continual B 12 every day and have no symptoms from week 8 to 12 so my quality of life has improved (P221, England)

, . . . I was very tired, lethargic, my brain felt like mush, hard to concentrate and breathlessness. Since self-injecting monthly I now have none of these symptoms. (P5, England)

Around a quarter of survey respondents had been prescribed B 12 replacement in an oral form. Patients voiced their concerns over the efficacy of this alternative source of B 12 ; it was unclear if an oral route would be effective at managing a condition caused by an inability to absorb dietary forms of B 12 . There was a perceived lack of evidence for the effectiveness of oral supplementation at controlling symptoms. Patients felt that the advice given by health care professionals about treatment during the pandemic conflicted with their understanding of the biological basis of the condition. The lack of confidence in the recommendation to move to oral supplementation is emphasized in the following quote . . . . the surgery may just as well have given me a bag of sweets (P11, England)

As a result of treatment changes, many patients reported having their injection suspended, they had been asked to undertake blood tests to confirm their need for replacement B 12 I was told last week due to Covid that I can't have it. Now after phoning today I'm told one doctor is looking at everyone who receives a B 12 injection is being referred to one doctor for blood tests to see if we still need it. (P652, Scotland)

In this sample, many respondents reported that their B 12 injections had been suspended; they had not received any form of treatment since the start of the pandemic and had not been offered an alternative treatment (n ¼ 121). These patients were angry and anxious; they were concerned that suspended treatment would lead to long-term neurological damage. Patients felt this was dangerous, for one individual the change was viewed as playing Russian Roulette with my health (P7, Wales).

As a result of the changes in PA treatment and subsequent delays in getting treatment reinstated, many reported experiencing worse and more frequent symptoms which impacted their quality of life (n ¼ 195).

All my symptoms worsened considerably, and I was struggling to function with daily activities and work (P144, England) They [symptoms] are much worse than before and I have episodes that leave me bed ridden (P26, Scotland).

Those who had been moved to oral B 12 noticed the return of symptoms which they had not experienced since their initial PA diagnosis.

When put on tablets I developed a shaking/tremor which I remembered suffering before I was diagnosed, belatedly after about three years. (P19, England) Further, a small number of participants mentioned developing new symptoms. The type of symptoms varied, ranging from physical to neurological symptoms. 

For most individuals, changes to their usual treatment were a source of fear, anxiety, and distress (Table 3) .

Many were dissatisfied with the way in which changes to treatment had been managed; the lack of shared decisionmaking made patients feel left out or overlooked. Only a small number of respondents reported that the decision to change their treatment had been made in response to a mutual discussion with their health care provider. This absence of shared decision-making made patients feel powerless.

Upset, angry and deeply worried. I was not consulted and have had to chase my surgery to find out what is happening at every stage (P134, England)

This study aimed to document changes in prescribed treatment for PA during the COVID-19 pandemic. The survey revealed that many health care settings had been able to safely continue to provide patients with their usual treatment by implementing social distancing measures. These changes align with the guidance set out by the British Society for Haematology which states that during the pandemic those with PA should continue to receive hydroxocobalamin injections where possible (4). However, despite this recommendation, over half of the survey respondents reported that they had experienced a change to their usual treatment. For most patients, this meant that their treatment had been suspended or that their hydroxocobalamin injections had been replaced with oral B 12 . Oral forms of B 12 were perceived to be less effective at managing symptoms.

This survey was able to document patient experiences of changes to their treatment during the pandemic across the United Kingdom. While no differences across regions were identified in terms of treatment changes; the provision of alternative treatments varied considerably between health care settings. In some settings, patients had been supported by their health care provider to self-administer hydroxocobalamin injections, while in others prescribed treatment had been completely withdrawn. The lack of a consistent approach to managing changes for this patient group has led to a disparity in patient care. The survey highlighted that it was common for patients to have been advised to manage their B 12 deficiency through diet or told to purchase dietary supplements. Some health care providers had requested that patients have their B 12 levels re-tested to confirm their PA diagnosis and this becomes problematic. Due to the lack of reliable clinical tests for PA, it is common for this patient group to have experienced challenging diagnostic journeys (12-14,) , therefore requests to retest may result in additional patient distress.

The chronicity of PA and the requirement for lifelong treatment were not always considered when making treatment changes, and this has disrupted the quality of life of several patients. Responses emphasized the importance of shared decision-making and the need to communicate changes in a way that addresses patients' concerns about their health (15) . Guidance by the British Society of Haematology also emphasizes the importance of discussing treatment changes during the pandemic (4). Providing patients with the opportunity to make shared decisions about their health care is empowering; however, in this sample, few participants had been involved in discussions of changes that would impact their health care. Shared decision-making can improve patient satisfaction and compliance with treatment regimens (15, 16) . The pandemic appears to have exacerbated existing patient concerns around discrepancies in diagnosis and management of PA within health care settings (17) .

Strengths of this research relate to the in-depth account of peoples' experiences of PA treatment during the pandemic. (18) . Nevertheless, the homogeneity of responses suggests that the views collected in this survey accurately reflect the issues experienced by people with a diagnosis of PA who have experienced treatment changes during the COVID-19 pandemic. This survey has a few limitations: the use of an online sample which was recruited in part by third-sector organizations may have led to potential self-selection bias as individuals who are unhappy with their medical care may be more likely to engage with support groups (19) . It is widely acknowledged that there is often a delay in diagnosing PA and that many individuals with nondietary forms of B 12 deficiency struggle to receive a clinical explanation for their symptoms (13, 14, 17) . This survey did not capture the experiences of individuals who have symptoms of nondietary B 12 deficiency but are not currently diagnosed with PA. As a patient group, these individuals are also likely to be impacted by the pandemic and experience challenges in accessing treatment.

This study captured patient perception of changes and although it has improved the understanding of the impact that the COVID-19 pandemic has had on PA treatment, further research is needed to explore these changes from the perspective of health care professionals. The future direction of this research is to gauge health care professionals' views on the challenges encountered in delivering replacement B 12 therapy during the pandemic. This study highlights the need to further educate health care professionals on the impact of PA on individuals' health-related quality of life. Development of NICE guidelines on the management of PA would also provide health care providers with clear indicators on how to support patient-centered approach to PA management.

Treatment changes because of the pandemic were perceived to be suboptimal to treat PA symptoms. This article highlights several learning points that can be applied to management beyond the pandemic.

Timely communication of treatment changes would help patients further understand the reasons why alternative treatment provisions may be implemented. Treatment changes should be patient-centered and consider individual health needs. Changes to standard care were a source of stress and anxiety for many patients. During emergency or pandemic situations, it is important to continue with shared decision-making and to include patients in decisions that are made about their health care. Health care professionals require education about PA so that changes made to treatment or care during emergency situations are evidence-based. Where treatment changes are required due to limited capacity within the health care service, alternative options such as self-administration of injections could be supported by adequate training to ensure patient safety.

Vitamin B12 deficiency as a worldwide problem

British Society for Haematology BSH Diagnosis of B12 and Folate Deficiency

Pernicious anaemia: mechanisms, diagnosis and management

British Society for Haematology. Guidance on Vitamin B12 replacement during the Covid-19 pandemic.British Society for Haematology

Pernicious Anaemia Society. Pernicious Anaemia and the coronavirus

UK Standards for Public Involvement in Research

Analysing Qualitative Data: Systematic Approaches

Three approaches to qualitative content analysis

Qualitative Content Analysis. Forum Qualitative Social Research

NVIVO 12 NVivo qualitative data analysis Software Version 12 Melbourne: QSR International Pty Ltd

Naturalistic inquiry. SAGE

Diagnosing vitamin B-12 deficiency on the basis of serum B-12 assay

A patient's journey: diagnosis and treatment of pernicious anaemia

Receiving a diagnosis of Pernicious Anaemia: Exploring experiences of relationships with healthcare professionals

Shared decision making: a model for clinical practice

Where is the evidence? A systematic review of shared decision making and patient outcomes

A patient and public involvement workshop using visual art and priority setting to provide patients with a voice to describe quality and safety concerns: Vitamin B12 deficiency and pernicious anaemia

Institute For Government 2020 Coronavirus and Devolution. Published by Institute for Government

Determinants of engagement in face-to-face and online patient support groups

The authors would like to thank all the study participants for their time and invaluable contribution to the study. The authors would also like to thank the Pernicious Anaemia Society for their support and useful feedback.

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

The author(s) received no financial support for the research, authorship, and/or publication of this article.

C H Seage https://orcid.org/0000-0002-8590-867X L Semedo https://orcid.org/0000-0003-0476-3112

Supplemental material for this article is available online.

CHS and LS developed the study concept and design, data collection, analysis, and interpretation. Both authors critically revised the manuscript and agreed to be accountable for all aspects of this work. The researchers would like to be considered as joint first authors of the manuscript. The current study received ethical approval from the School of Sport and Health Science Ethics Committee, Cardiff Metropolitan University (reference STa-2872). All procedures in this study were conducted in accordance with the School of Sport and Health Sciences Ethics Committee. Written informed consent was obtained from the patient(s) for their anonymized information to be published in this article.

Catherine Heidi Seage is a chartered psychologist and senior lecturer in health psychology.Lenira Semedo is a chartered psychologist and researcher in public health.